Here's what Jason has been saying this month on Amarantus:
Quote:Our take on the story is that there is simply too much going on at Amarantus to keep the stock under ten cents for much longer.
Quote:Speaking of credibility, the recent news that the U.S. FDA granted MANF an Orphan Drug designation for Retinitis Pigmentosa (RP) in late December 2014 was a huge win for Amarantus.
Quote:Amarantus is now loaded with catalysts.